Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health director Manuel Hidalgo Medina reported a routine equity award vesting. On January 17, 2026, 232 Restricted Stock Units converted at an exercise price of $0 into 232 shares of common stock. After this transaction, he beneficially owned 1,261 shares of common stock directly and 6,961 Restricted Stock Units.
The Restricted Stock Units were granted on July 17, 2024 and vest over four years. 25% of the award vested on the one-year anniversary of that grant date, and the remaining 75% vests in equal monthly installments over the following three years.
Guardant Health director Musa Tariq reported the vesting and conversion of 250 restricted stock units into 250 shares of common stock at a price of $0 per share on January 15, 2026. Following this transaction, he directly owns 8,243 shares of Guardant Health common stock and 3,498 restricted stock units. The RSUs were granted on March 6, 2023 and vest over four years: 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the subsequent three-year period.
Guardant Health reported that Chief People Officer Terilyn J. Monroe had 17,379 Restricted Stock Units settle into 17,379 shares of Common Stock on January 15, 2026. Of these, 8,808 shares were retained by the company at $111.98 per share to satisfy tax withholding obligations, and she now holds 29,561 shares of Common Stock directly. The underlying RSU award was granted on February 26, 2024 and vests 33% on the one-year anniversary of January 15, 2024, with the remaining 67% vesting annually over the following two-year period.
Guardant Health, Inc. reported that on January 11, 2026 it announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2025. This information is provided in a press release that is furnished as Exhibit 99.1 to the report, rather than being formally filed, which limits how it is incorporated into other regulatory documents.
The company also disclosed that it will post the investor presentation used at the 2026 J.P. Morgan Healthcare Conference, scheduled for January 12, 2026, on its website under the Investors section. These updates are intended to give the market an early view of recent performance and the materials being shared with investors.
Guardant Health’s Chief People Officer, Terilyn J. Monroe, reported selling common stock in three transactions on January 7, 2026. She sold 6,311 shares at a weighted average price of $111.7521 per share, 3,632 shares at $112.6182 per share, and 88 shares at $113.4397 per share. After these sales, she held 20,990 shares of Guardant Health common stock directly. The prices reported are weighted averages for multiple trades within disclosed price ranges.
Guardant Health, Inc. insider Terilyn J. Monroe has filed a notice to sell 10,031 shares of Guardant Health common stock. The planned sale is to be executed through Charles Schwab & Co., Inc., on NASDAQ, with an indicated aggregate market value of $1,124,200.00 and 126,041,089 shares of Guardant Health common stock shown as outstanding.
The shares to be sold were acquired on 01/01/2026 through equity compensation, including 8,720 shares from a performance stock lapse and 1,311 shares from a restricted stock lapse, both from Guardant Health, Inc. The filing also shows that Monroe previously sold 55,167 Guardant Health shares on 12/01/2025 for gross proceeds of $5,846,164.00.
Guardant Health, Inc. director reports RSU vesting and share acquisition. On 12/17/2025, reporting person Manuel Hidalgo Medina acquired 232 shares of Guardant Health common stock at a price of $0 through the settlement of previously granted restricted stock units, reported with transaction code M.
The restricted stock units were granted on July 17, 2024 and vest over four years, with 25% of the shares vesting on the one-year anniversary of that date and the remaining 75% vesting monthly over the following three years. After this transaction, the reporting person beneficially owns 1,029 shares of common stock directly and 7,193 restricted stock units.
Guardant Health, Inc. director Musa Tariq disclosed a small sale of company stock. On 12/17/2025, the reporting person sold 116 shares of Guardant Health common stock at a price of $101.46 per share. After this transaction, the director beneficially owned 7,993 shares of Guardant Health common stock, held in direct ownership. This filing is a routine insider ownership update and does not describe any additional transactions or derivative securities.
Guardant Health, Inc. director reports routine vesting of restricted stock units. On 12/15/2025, a reporting person who serves as a director of Guardant Health, Inc. (ticker GH) acquired 250 shares of common stock at a price of $0 through the vesting and settlement of previously granted restricted stock units. After this transaction, the director beneficially owned 8,109 shares of common stock directly and 3,748 restricted stock units that remain outstanding.
The restricted stock units were originally granted on March 6, 2023 and vest over four years. According to the vesting schedule, 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting in equal monthly installments over the following three-year period.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported equity compensation activity on December 15, 2025. 1,020 Restricted Stock Units converted into common stock at $0 per share, and 535 common shares were withheld by the company to meet tax withholding obligations at $102.67 per share, as explained in a footnote. After these transactions he directly holds 43,657 shares of Guardant Health common stock.